{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:11:51Z","timestamp":1792789911232,"version":"4.5.0"},"reference-count":27,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japanese Grant-in-Aid for Scientific Research","award":["24K12260"],"award-info":[{"award-number":["24K12260"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology International"],"abstract":"<jats:p>Background\/Objectives: Lasmiditan is a newly developed drug for the acute treatment of migraine attacks, but factors associated with its efficacy remain unclear. This study aimed to confirm the efficacy of lasmiditan started at 50 mg under various dosing conditions and identify factors associated with its efficacy. Methods: There are four reasons for prescribing lasmiditan: as an add-on to triptan, if triptan is ineffective, if triptan produces side effects, and when triptan is contraindicated. Lasmiditan was administered at a dose of 50 mg. The efficacy of lasmiditan was defined as the disappearance of headache or a 50% or greater reduction in headache intensity within two hours after dosing. This study included 108 patients with migraines who took lasmiditan. Results: The results for efficacy and the side effects of lasmiditan were as follows: effective without side effects (22), effective with mild side effects (32), ineffective (14), and severe side effects (40). The efficacy rate of lasmiditan 50 mg was 50.0% (54\/108). The following factors were found to be associated with lasmiditan\u2019s efficacy: sex, migraine classification, calcium channel blockers, and anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment. The overall incidence of side effects was 66.7%, and the dropout rate was 37.0%. Somnolence was more prevalent in the effective group, and other side effects were more prevalent in patients who dropped out due to the side effects of lasmiditan. Conclusions: Lasmiditan is likely to be effective in males with severe migraine classification and receiving CGRP-mAb treatment. If mild somnolence is a side effect, the drug can be continued and may be effective.<\/jats:p>","DOI":"10.3390\/neurolint17050062","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T20:24:52Z","timestamp":1745353492000},"page":"62","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9251-4230","authenticated-orcid":false,"given":"Takafumi","family":"Tanei","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"},{"name":"Department of Specialized Headache Outpatient, Nagoya Garden Clinic, Nagoya 451-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Maesawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"},{"name":"Department of Neurosurgery, National Hospital Organization, Nagoya Medical Center, Nagoya 460-0001, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-0586","authenticated-orcid":false,"given":"Yusuke","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-1663","authenticated-orcid":false,"given":"Yoshitaka","family":"Nagashima","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Hashida","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Hamasaki","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Department of Specialized Headache Outpatient, Nagoya Garden Clinic, Nagoya 451-0051, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-1360","authenticated-orcid":false,"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: Epidemiology and systems of care","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","article-title":"Hallmarks of primary headache: Part 1\u2014Migraine","volume":"25","author":"Raggi","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","article-title":"Disability, quality of life, productivity impairment and employer costs of migraine in the workplace","volume":"22","author":"Shimizu","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A Controlled Trial of Erenumab for Episodic Migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/head.14178","article-title":"Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/head.14138","article-title":"Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"61","author":"Takeshima","year":"2021","journal-title":"Headache"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e40190","DOI":"10.1016\/j.heliyon.2024.e40190","article-title":"Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization","volume":"10","author":"Tanei","year":"2024","journal-title":"Heliyon"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1526-4610.2011.02062.x","article-title":"Rescue therapy for acute migraine, part 1: Triptans, dihydroergotamine, and magnesium","volume":"52","author":"Kelley","year":"2012","journal-title":"Headache"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1526-4610.2002.0420s1010.x","article-title":"Clinical benefits of early triptan therapy for migraine","volume":"42","author":"Pascual","year":"2002","journal-title":"Headache"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s10194-020-01132-3","article-title":"Lasmiditan mechanism of action\u2014Review of a selective 5-HT1F agonist","volume":"21","author":"Clemow","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-022-01394-z","article-title":"Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors","volume":"23","author":"Edvinsson","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/head.14122","article-title":"Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s10194-024-01904-1","article-title":"Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: Systematic review and network meta-analysis","volume":"25","author":"Laohapiboolrattana","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2732","DOI":"10.1002\/hup.2732","article-title":"Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls","volume":"35","author":"Pearlman","year":"2020","journal-title":"Hum. Psychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/head.13897","article-title":"Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks","volume":"60","author":"Tepper","year":"2020","journal-title":"Headache"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0333102421989232","article-title":"Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/head.13544","article-title":"Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials","volume":"59","author":"Tepper","year":"2019","journal-title":"Headache"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3390\/neurolint16030048","article-title":"Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan","volume":"16","author":"Shibata","year":"2024","journal-title":"Neurol. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3331024241258695","DOI":"10.1177\/03331024241258695","article-title":"Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan","volume":"44","author":"Ishii","year":"2024","journal-title":"Cephalalgia"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","article-title":"Association between response to triptans and response to erenumab: Real-life data","volume":"22","author":"Frattale","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","article-title":"Acute Migraine: Can the New Drugs Clinically Outpace?","volume":"2","author":"Singh","year":"2020","journal-title":"SN Compr. Clin. Med."}],"container-title":["Neurology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2035-8377\/17\/5\/62\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:19:22Z","timestamp":1760030362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2035-8377\/17\/5\/62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["neurolint17050062"],"URL":"https:\/\/doi.org\/10.3390\/neurolint17050062","relation":{},"ISSN":["2035-8377"],"issn-type":[{"value":"2035-8377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}